CY1105600T1 - Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση - Google Patents
Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιησηInfo
- Publication number
- CY1105600T1 CY1105600T1 CY20061100494T CY061100494T CY1105600T1 CY 1105600 T1 CY1105600 T1 CY 1105600T1 CY 20061100494 T CY20061100494 T CY 20061100494T CY 061100494 T CY061100494 T CY 061100494T CY 1105600 T1 CY1105600 T1 CY 1105600T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nucleic acid
- molecules
- acid constructs
- genetic immunization
- sequence encoding
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Περιγράφονται ανασυνδυασμένα μόρια νουκλεϊκών οξέων. Τα μόρια έχουν μία πρώτη αλληλουχία που κωδικοποιεί αντιγόνο πυρήνα ιού ηπατίτιδας Β και δεύτερη αλληλουχία που κωδικοποιεί τουλάχιστον ένα επίτοπο Τ-λεμφοκυττάρων ενθεμένη στην πρώτη αλληλουχία. Περιγράφονται επίσης φορείς και συνθέσεις που περιέχουν αυτά τα μόρια. Περιγράφονται επίσης μέθοδοι εκμαίευσης ανοσοαπόκρισης χρησιμοποιώντας αυτά τα μόρια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10716998P | 1998-11-05 | 1998-11-05 | |
PCT/US1999/026291 WO2000026385A1 (en) | 1998-11-05 | 1999-11-05 | Nucleic acid constructs for genetic immunization |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105600T1 true CY1105600T1 (el) | 2010-07-28 |
Family
ID=22315199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100494T CY1105600T1 (el) | 1998-11-05 | 2006-04-07 | Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1119630B1 (el) |
JP (1) | JP2002528123A (el) |
AT (1) | ATE315658T1 (el) |
AU (1) | AU775939B2 (el) |
CA (1) | CA2349505A1 (el) |
CY (1) | CY1105600T1 (el) |
DE (1) | DE69929470T2 (el) |
DK (1) | DK1119630T3 (el) |
ES (1) | ES2257879T3 (el) |
IL (1) | IL142980A0 (el) |
NZ (1) | NZ512078A (el) |
PT (1) | PT1119630E (el) |
WO (1) | WO2000026385A1 (el) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6933366B2 (en) | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
EP1220697B1 (en) | 1999-10-11 | 2004-12-29 | Felton International, Inc. | Universal anti-infectious protector for needleless injectors |
US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
AU2001266163B2 (en) * | 2000-06-22 | 2006-07-13 | Celltech Pharmaceticals Limited | Modification of hepatitis b core antigen |
EP1354033A2 (en) * | 2000-09-19 | 2003-10-22 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
WO2002094313A2 (en) * | 2001-05-18 | 2002-11-28 | Powderject Vaccines, Inc. | Vaccine composition |
DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
BR0314751A (pt) | 2002-09-27 | 2005-07-26 | Powderject Res Ltd | Partìculas adequadas para suprimento a partir de um dispositivo de suprimento, receptáculo de dosagem para um dispositivo de suprimento, dispositivo de suprimento mediado por partìcula, processo para a preparação de partìculas adequadas para suprimento a partir de um dispositivo de suprimento, e, métodos de imunização por ácido nucleico e de terapia genética |
US7335359B2 (en) | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
JP2007516157A (ja) | 2003-02-06 | 2007-06-21 | トリペップ アクチ ボラゲット | グリコシル化された抗原/抗体又はリガンド/受容体特異性交換体 |
WO2008043157A1 (en) | 2006-10-12 | 2008-04-17 | The University Of Queensland | Compositions and methods for modulating immune responses |
JP5209800B2 (ja) | 2008-12-09 | 2013-06-12 | ファイザー バクシーンズ エルエルシー | IgECH3ペプチドワクチン |
CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
NZ620441A (en) | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
CA2816529A1 (en) | 2010-11-01 | 2012-05-10 | University Of Technology, Sydney | Immune-modulating agents and uses therefor |
CN103442732B (zh) | 2011-02-11 | 2017-04-12 | 宾夕法尼亚大学托管会 | 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗 |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
-
1999
- 1999-11-05 AU AU20222/00A patent/AU775939B2/en not_active Ceased
- 1999-11-05 DE DE69929470T patent/DE69929470T2/de not_active Expired - Lifetime
- 1999-11-05 CA CA002349505A patent/CA2349505A1/en not_active Abandoned
- 1999-11-05 IL IL14298099A patent/IL142980A0/xx unknown
- 1999-11-05 NZ NZ512078A patent/NZ512078A/xx not_active IP Right Cessation
- 1999-11-05 JP JP2000579757A patent/JP2002528123A/ja active Pending
- 1999-11-05 ES ES99963869T patent/ES2257879T3/es not_active Expired - Lifetime
- 1999-11-05 DK DK99963869T patent/DK1119630T3/da active
- 1999-11-05 EP EP99963869A patent/EP1119630B1/en not_active Expired - Lifetime
- 1999-11-05 AT AT99963869T patent/ATE315658T1/de not_active IP Right Cessation
- 1999-11-05 PT PT99963869T patent/PT1119630E/pt unknown
- 1999-11-05 WO PCT/US1999/026291 patent/WO2000026385A1/en active IP Right Grant
-
2006
- 2006-04-07 CY CY20061100494T patent/CY1105600T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022200A (en) | 2000-05-22 |
ES2257879T3 (es) | 2006-08-01 |
AU775939B2 (en) | 2004-08-19 |
EP1119630A1 (en) | 2001-08-01 |
DE69929470D1 (de) | 2006-04-06 |
ATE315658T1 (de) | 2006-02-15 |
NZ512078A (en) | 2004-01-30 |
PT1119630E (pt) | 2006-05-31 |
JP2002528123A (ja) | 2002-09-03 |
CA2349505A1 (en) | 2000-05-11 |
IL142980A0 (en) | 2002-04-21 |
WO2000026385A1 (en) | 2000-05-11 |
DK1119630T3 (da) | 2006-05-15 |
DE69929470T2 (de) | 2006-08-24 |
EP1119630B1 (en) | 2006-01-11 |
WO2000026385A9 (en) | 2000-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105600T1 (el) | Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση | |
NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
DK0460076T3 (da) | Genetisk manipulerede immunoglobuliner | |
CY1105685T1 (el) | Συνδεομενα με ογκους αντιγονικα παραγωγα απο την οικογενεια mage, και ακολουθιες νουκλεϊκων οξεων που τα κωδικοποιουν, χρησιμοποιουμενα στην παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο | |
ATE303160T1 (de) | Impfstoff gegen prostatakrebs | |
ATE214601T1 (de) | Rekombinantes vielwertiges m-protein-vakzin | |
ATE475668T1 (de) | Immunisierung durch impfung von dns transkriptionseinheit | |
CY1112658T1 (el) | Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d | |
ATE302016T1 (de) | Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind | |
NZ213303A (en) | Plasmodium protein, dna sequence and vaccine | |
NL300336I1 (nl) | Vaccin tegen de bof dat een jeryl-lynn virusstam bevat | |
WO2000063385A3 (en) | Nucleic acid immunization | |
ATE421331T1 (de) | Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff | |
DK0691404T3 (da) | Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf | |
AU686000B2 (en) | Infectious peritonitis vaccine | |
DK1227840T3 (da) | Adjuverede, genetiske vacciner | |
ATE460945T1 (de) | Genetische adjuvanz-impfstoffe |